Niemelä, M <br/><br/>
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.  [electronic resource] 

 -  Oncogene  Sep 2012 
 - 4266-78 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2011.599  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Autoantigens--metabolism<br/>Breast Neoplasms--drug therapy<br/>Cell Proliferation--drug effects<br/>Female<br/>Gene Expression Profiling<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Intracellular Signaling Peptides and Proteins<br/>Membrane Proteins--metabolism<br/>Mitogen-Activated Protein Kinase 9--biosynthesis<br/>Protein Phosphatase 2--metabolism<br/>Proto-Oncogene Proteins c-myc--metabolism<br/>RNA, Small Interfering--pharmacology<br/>Receptor, ErbB-2--analysis<br/>Signal Transduction--drug effects<br/>Tumor Cells, Cultured